WO2006048893A3 - Processus de synthese de composes statine a particules de grande taille - Google Patents

Processus de synthese de composes statine a particules de grande taille Download PDF

Info

Publication number
WO2006048893A3
WO2006048893A3 PCT/IN2005/000359 IN2005000359W WO2006048893A3 WO 2006048893 A3 WO2006048893 A3 WO 2006048893A3 IN 2005000359 W IN2005000359 W IN 2005000359W WO 2006048893 A3 WO2006048893 A3 WO 2006048893A3
Authority
WO
WIPO (PCT)
Prior art keywords
synthesis
particle size
large particle
statin compounds
solvent
Prior art date
Application number
PCT/IN2005/000359
Other languages
English (en)
Other versions
WO2006048893A2 (fr
Inventor
Sanjay Suri
Gurdeep Singh Sarin
Original Assignee
Morepen Lab Ltd
Sanjay Suri
Gurdeep Singh Sarin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morepen Lab Ltd, Sanjay Suri, Gurdeep Singh Sarin filed Critical Morepen Lab Ltd
Publication of WO2006048893A2 publication Critical patent/WO2006048893A2/fr
Publication of WO2006048893A3 publication Critical patent/WO2006048893A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention concerne un processus de synthèse de composés statine à particules de grande taille qui consiste à ajouter une solution du composé statine souhaité de forme cristalline ou de forme amorphe, éventuellement obtenu de leurs intermédiaires par des procédés connus, de solvant organiques en anti-solvant, par mélange, le solvant étant éventuellement évaporé, à isoler le composé cité par centrifugation suivie par le séchage sous vide. Ce processus est plus particulièrement destiné à la synthèse du calcium d'atorvastatine et du sodium de fluvastatine.
PCT/IN2005/000359 2004-11-05 2005-11-03 Processus de synthese de composes statine a particules de grande taille WO2006048893A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2206DE2004 2004-11-05
IN2206/DEL/2004 2004-11-05

Publications (2)

Publication Number Publication Date
WO2006048893A2 WO2006048893A2 (fr) 2006-05-11
WO2006048893A3 true WO2006048893A3 (fr) 2006-07-13

Family

ID=36120262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2005/000359 WO2006048893A2 (fr) 2004-11-05 2005-11-03 Processus de synthese de composes statine a particules de grande taille

Country Status (1)

Country Link
WO (1) WO2006048893A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006109147A1 (fr) * 2005-04-12 2006-10-19 Glenmark Pharmaceuticals Limited Fluvastatine amorphe pratiquement pure, procede de preparation et compositions pharmaceutiques qui la contiennent
CN100429202C (zh) * 2006-06-30 2008-10-29 浙江新东港药业股份有限公司 一种无定形氟伐他汀钠的制备方法
ES2321571B1 (es) * 2007-07-18 2010-03-11 Ercros Industrial, S.A. Solvatos de fluvastatina sodica y su utilizacion como intermedios en la obtencion de fluvastatina sodica amorfa.
WO2011131601A1 (fr) * 2010-04-19 2011-10-27 Dsm Ip Assets B.V. Production d'atorvastatine à faible teneur en impuretés lactones
CN103108863B (zh) * 2010-04-19 2015-08-19 中化帝斯曼制药有限公司荷兰公司 低醚杂质的阿托伐他汀的制备
WO2011154009A1 (fr) * 2010-06-10 2011-12-15 Lifecycle Pharma A/S Composition comprenant un principe actif sous une forme amorphe et une substance poreuse adsorbante
CN102351771B (zh) * 2011-08-11 2013-07-03 天津市汉康医药生物技术有限公司 高生物利用度的阿托伐他汀钙化合物
CN106432033B (zh) * 2016-10-21 2018-07-27 江苏阿尔法药业有限公司 一种无定形阿托伐他汀钙的制备方法
CN115043769A (zh) * 2022-06-28 2022-09-13 江苏阿尔法药业股份有限公司 一种阿托伐他汀钙的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042209A1 (fr) * 1999-12-10 2001-06-14 Lek Pharmaceutical And Chemical Company D.D. Procede de preparation d'atorvastatine amorphe
WO2003018547A2 (fr) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
WO2003068739A1 (fr) * 2002-02-01 2003-08-21 Zentiva A.S. Procede de fabrication d'une forme amorphe du sel d'hemicalcium d'acide (3r, 5r) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-l-yl]-3, 5-dihydroxyheptanoique (atorvastatine)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042209A1 (fr) * 1999-12-10 2001-06-14 Lek Pharmaceutical And Chemical Company D.D. Procede de preparation d'atorvastatine amorphe
WO2003018547A2 (fr) * 2001-08-31 2003-03-06 Morepen Laboratories Ltd. Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
WO2003068739A1 (fr) * 2002-02-01 2003-08-21 Zentiva A.S. Procede de fabrication d'une forme amorphe du sel d'hemicalcium d'acide (3r, 5r) 7-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-l-yl]-3, 5-dihydroxyheptanoique (atorvastatine)

Also Published As

Publication number Publication date
WO2006048893A2 (fr) 2006-05-11

Similar Documents

Publication Publication Date Title
WO2006048893A3 (fr) Processus de synthese de composes statine a particules de grande taille
WO2006066839A3 (fr) Procede pour produire des pyrrolidones a partir de succinates issus de bouillons de fermentation
US20100197941A1 (en) Process for the production of atorvastatin calcium in amorphous form
IL182449A0 (en) Process for conversion of organic, waste, or low value materials into useful products
HK1045118A1 (zh) 無定形的阿伐他汀鈣的製備方法
WO2012002741A3 (fr) Procédé de préparation d'inhibiteurs de la hmg-coa réductase et leurs intermédiaires
WO2005062897A3 (fr) Formes polymorphes d'ezetimibe et procedes de preparation de celles-ci
WO2007047671A3 (fr) Tetrahydroquinolines, synthese de celles-ci et produits intermediaires correspondants
WO2003018547A3 (fr) Procede ameliore de preparation d'un sel d'atorvastatine calcique amorphe (2:1)
MXPA04005603A (es) Sal cristalina de calcio del acido (r-(r*, r*) (-2- (4-fluorofenil)- (,(- dihidroxi- 5(1- metiletil)- 3-fenil -4-((fenilamino) carbonil (-1h-pirrol -heptanoico (2:1).
WO2004050618A3 (fr) Forme cristalline
WO2007052309A3 (fr) Processus ameliore de fabrication de statines
WO2005018573A3 (fr) Derives de 6-cycloamino-2-quinolinone utilises comme composes modulateurs des recepteurs d'androgenes
WO2007003200A3 (fr) Procedes de synthese a rendement eleve destines a la production de sels organiques de strontium
EA200800916A1 (ru) СПОСОБ СИНТЕЗА ИНГИБИТОРОВ HMG-CoA РЕДУКТАЗЫ
WO2006122644A3 (fr) Procede de production de statines
WO2007029084A3 (fr) Composes de carpapenem: operation amelioree de fabrication
WO2007031845A3 (fr) Formes polymorphiques de sels de magnesium de (s)-omeprazole et procedes de preparation desdites formes
AU2003210277A1 (en) Environment friendly reagents and process for trifluoromethylsulfinylation of organic compounds
AU2002367103A1 (en) An improved synthesis of ceftiofur intermediate
Böhme et al. Synthesis of the antibiotic (R)‐Reutericyclin via Dieckmann condensation
WO2001092265A3 (fr) Composes d'indolinospiropyrane et procede de preparation associe
WO2007017244A3 (fr) Procede d'elaboration de composes 2-(2-pyridylmethyl)sulfinyl-1h-benzimidazoliques substitues
WO2007096903A3 (fr) Nouvelle forme cristalline d'hemi-calcium d'atorvastatine
IL186499A (en) Processes for the preparation of a crystalline form of atorostatin mycelium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05812688

Country of ref document: EP

Kind code of ref document: A2